Introduction
Nasopharyngeal carcinoma (NPC) is a highly invasive malignancy characterized by complex mechanisms of immune evasion. A critical component of this evasion is the expression of immune checkpoint molecules that allow tumor cells to bypass host surveillance. This research investigates the role of PDZ-binding kinase (PBK), an enzyme frequently overexpressed in various cancers, as a master regulator of the immune checkpoint molecule CD276 (B7-H3) in NPC.
The PBK-MSL1-CD276 Signaling Axis
The study identifies a specific signaling pathway where PBK influences the epigenetic landscape of NPC cells. The researchers propose that PBK phosphorylates MSL1, which in turn triggers epigenetic modifications—such as histone alterations—that activate the transcription of the CD276 gene. This axis (PBK → MSL1 → CD276) represents a novel mechanism by which NPC cells modulate gene expression to favor tumor progression and immune resistance.
Experimental Validation and Correction
To validate this relationship, the authors utilized loss-of-function and gain-of-function assays. Silencing PBK via siRNA led to a significant reduction in CD276 levels, while rescue experiments using wild-type PBK restored expression. Notably, the phosphorylation of PBK at the T198 site is essential for this regulatory function; a non-phosphorylatable mutant (T198A) failed to rescue CD276 expression, whereas a phosphomimetic mutant (T198E) successfully restored it.
This document serves as a formal correction to the original 2021 publication, specifically addressing a data presentation error in the Western blots of Figure 2B. The corrected figure provided above ensures the integrity of the evidence supporting PBK's role in regulating CD276 protein levels.
Therapeutic Potential and Clinical Relevance
The regulatory role of PBK was further confirmed through pharmacological inhibition and overexpression studies. Treatment with OTS514, a potent and selective PBK inhibitor, resulted in a dose-dependent decrease in CD276 mRNA and protein levels across multiple NPC cell lines (CNE2, SUNE1). Conversely, overexpressing PBK in CNE1 and HK1 cells significantly upregulated CD276.
Clinical data analysis reinforced these laboratory findings. In a cohort of 113 NPC samples, a statistically significant positive correlation was observed between PBK and CD276 expression levels (p=0.0006). These results suggest that PBK levels could serve as a valuable biomarker for CD276-mediated immune evasion and that targeting the PBK-MSL1 axis may enhance the efficacy of immunotherapies in NPC patients.
Summary updated